Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: Covid19, Cancer, Malignancy, Vaccine Response Impaired
Interventions: SARS-COV2 Pfizer Vaccine; Biological
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS), Cancer
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mild-to-moderate COVID-19
Interventions: KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 16
States / cities: Hot Springs, Arkansas • Riverside, California • San Diego, California + 12 more

Conditions: Asthma
Interventions: Reslizumab, Saline; Biological · Other
Lead sponsor: Ception Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more

Conditions: Covid19, Respiratory Failure
Interventions: Proning, Supportive Care; Behavioral · Other
Lead sponsor: New York Hospital Queens; Other
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Flushing, New York

Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Franz Rischard, DO; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: HRD Cancer, SCLC, Advanced Solid Tumors
Interventions: Berzosertib, Sacituzumab Govitecan; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Undiagnosed Pulmonary Nodules, Lung Nodules
Interventions: CT Scan; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Covid-19, ARDS, Human, Acute Lung Injury
Interventions: Heparin, 0.9% Sodium-chloride; Drug
Lead sponsor: Frederick Health; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Acute Respiratory Distress Syndrome, Diaphragm Injury, Neuromuscular Blockade
Interventions: Not listed
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Boston, Massachusetts • Springfield, Massachusetts • Cleveland, Ohio + 3 more

Conditions: COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Survey Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Tobacco Dependence
Interventions: C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening; Behavioral · Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Smell Dysfunction, Olfactory Disorder, Long COVID
Interventions: Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO); Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan, Placebo, Sildenafil, Tadalafil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 30
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: COVID-19
Interventions: Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Pneumonia, Critical Illness
Interventions: Not listed
Lead sponsor: Critical Care Pharmacotherapy Trials Network; Other
Eligibility: 18 Years to 89 Years
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 29
States / cities: Little Rock, Arkansas • Hartford, Connecticut • Jacksonville, Florida + 24 more

Conditions: Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
Interventions: Cerdulatinib, Rituximab; Drug · Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 23
States / cities: Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more

Conditions: Carcinoma, Non-small-cell Lung
Interventions: erlotinib and bexarotene; Drug
Lead sponsor: Konstantin Dragnev; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 2
States / cities: Lebanon, New Hampshire • New York, New York

Conditions: Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia, Osteoporosis, Iron Overload, Hypertension, Pulmonary
Interventions: Deferoxamine, Deferiprone, Arginine, Sildenafil, Decitabine; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 1 Year to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 4
States / cities: Oakland, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Non Small Cell Lung Cancer
Interventions: LN-145, Durvalumab; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more

Conditions: Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Interventions: AGuIX, Radiotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: COVID-19, Mechanical Ventilation
Interventions: Dornase Alfa; Drug
Lead sponsor: Feinstein Institute for Medical Research; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions: [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab; Drug · Biological
Lead sponsor: Fusion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more

Search by objective public record fields.

Immune Response to the COVID-19 Vaccine

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

3-D Reconstruction of CT Scan Images in the Evaluation of Non-Specific Pulmonary Nodules

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

Re-Evaluation of Systemic Early Neuromuscular Blockade and Transthoracic Ultrasound Assessment of the Diaphragm

The Impact of COVID-19 on Pulmonary Procedures

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

C-Raven, a Virtual Tobacco Cessation Intervention in the Community

Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

Drug Resistance Factors In Healthcare-associated Pneumonia

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Dornase Alfa Administered to Patients With COVID-19 (DACOVID)

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours